Abstract: The invention relates to a complex between block polymers comprising a first hydrophilic block and a second block comprising at least one ionised function, and optionally carrying at least one additional chemical or biochemical group or comprising a third polymer block, and mixtures of said polymers, and ions selected from the elements Cu, Ga, Sr, Bi, Se, Y, lanthanide, Pb, Te, Zn, Zr at different degrees of ionisation and the mixtures thereof, more particularly for the use thereof in medical imaging, and to a production method and a physiologically acceptable composition containing said complex.

Abstract: Dendrimers with monophosphonic or bisphosphonic terminations for the treatment of inflammatory diseases.

Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.

Abstract: A method for preparing a composition includes silico/germano-metal particles functionalized by at least one organic group, which involves:—carrying out a hydrothermal treatment of a hydrogel precursor of the silico/germano-metal mineral particles, and—preparing a hydrogel including silico/germano-metal particles having at least one organic group by co-precipitation in an aqueous medium. A composition including functionalized silico/germano-metal mineral particles of which 1% to 75% of the silicon atoms and/or of the germanium atoms are covalently bonded to at least one organic group is also described.

Abstract: The present invention relates to methods and compositions for the prevention or treatment of neurodegenerative diseases.

Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

Abstract: Method for producing a directed monolayer or multilayer assembly of colloidal nanoparticles attached to an electret substrate, including imparting a surface electric potential to an electret substrate according to a pattern of positive and/or negative electric charges, and contacting an electret substrate with a colloidal dispersion. The colloidal dispersion has electrically neutral or near neutral and electrically polarizable colloidal nanoparticles, and a nonpolarizing or weakly polarizing dispersion medium. The absolute value of the surface electric potential and the concentration of polarizable nanoparticles are no lower than a first surface electric potential threshold and no lower than a second concentration threshold, respectively, such as to obtain an assembly having a desired geometric shape, at least the first layer of which is compact in terms of the absence of undesired gaps having sizes greater than the size of two adjacent nanoparticles, preferably not greater than the size of one nanoparticle.

Abstract: A method for preparing a novel hydrogel including silico-metallic mineral particles of the formula (Six(Si-A)1?x)4M3O11.n?H2O, in which: x is a real number in the range [0.75; 1], A denotes a group selected from methyl and hydrocarbon groups including at least one heteroatom, and M is a metal selected from the group consisting of magnesium, cobalt, zinc, copper, manganese, iron, nickel and chromium, wherein a coprecipitation reaction is carried out in an aqueous medium between: at least one metal salt of the metal M, sodium metasilicate, Na2OSiO2, and at least one water-soluble oxysilane of formula (I): in which R1, R2 and R3 are selected from hydrogen and linear alkyl groups including 1 to 3 carbon atoms.

Abstract: A method for processing plant matter, which involves applying a processing composition including at least one biological agent selected from: bacteria including a DNA sequence, referred to as 16S rDNA, coding for the 16S ribosomal RNA of the bacterium, which is 100% homologous with SEQ ID NO. 1, culture media in which bacteria have grown which include the 16S rDNA sequence that is 100% homologous with SEQ ID NO. 1 and which are substantially free of the bacteria, the culture media including polynucleotides having a DNA sequence which is 100% homologous with SEQ ID NO. 1, and in which the bacteria are selected from bacteria that are consistent with the strain filed and registered on 7 Apr. 2011 with number 1-4467 before the French National Collection of Microorganism Cultures (CNCM) of the Pasteur Institute, and mutant bacteria of the filed strain.

Abstract: A process for preparing a composition including synthetic mineral particles, in which a hydrogel which is a precursor of the synthetic mineral particles is prepared via a coprecipitation reaction between at least one compound including silicon, and at least one compound including at least one metal element, characterized in that the coprecipitation reaction takes place in the presence of at least one carboxylate salt of formula R2—COOM? in which: —M? denotes a metal chosen from the group made up of Na and K, and —R2 is chosen from H and alkyl groups including fewer than 5 carbon atoms. A composition including synthetic mineral particles which is obtained by such a process is also described.

Abstract: A copolymer having amphiphilic blocks includes at least one first hydrophilic block, obtainable from n-butyl acrylate and hydroxyethyl methacrylate monomers, and a second hydrophobic block likely to be obtained from a methyl methacrylate monomer. The copolymer is found to be particularly advantageous for use as an additive for manufacturing a polymer filtration membrane, particularly a PVDF membrane, particularly via a phase inversion method.

Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.

Abstract: A device for purifying liquid wastewater, includes: a container suitable for retaining a granulate consisting of solid particles, and for enabling the contact between the solid particles of the granulate and the liquid wastewater flowing in the container between: an inlet for the liquid wastewater to flow into the container, and an outlet for substantially decontaminated water to flow out of the container; a community of microorganisms extending so as to be in contact with the solid particles of the granulate; at least one live benthic invertebrate whose mean size is greater than 250 ?m and which is distributed in the granulate; and at least one live benthic invertebrate whose mean size is from 50 ?m to 250 ?m and which is distributed in the granulate, characterized in that the community of macrobenthic organism and meiobenthic organism species includes a proportion of 60% to 80% of invertebrate detrivorous organisms.

Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.

Abstract: The present invention concerns the development of a model to evaluate active substances targeting the epidermis. It more particularly relates to the preparation of mixed spheroids of melanocytes and keratinocytes reproducing cell interactions occurring in the epidermis, to the spheroids as such and to the uses thereof.

Abstract: The invention relates to a composition which contains an aqueous solution of certain elements of a family of sterol derivatives, which enable improved tanning of the skin due to considerable penetration of the molecules thereof. Preferably, the composition also contains an ionic solution of cationic association complexes constituting an acid amphiphilic carrier.

Abstract: A method for the heterogeneous catalysis of a chemical reaction using, in a reactor, at least one reagent and a catalytic composition that can catalyze the reaction within a given range of temperatures T. At least one reagent is brought into contact with the catalytic composition which includes a ferromagnetic nanoparticulate component whose surface is formed at least partially by a compound that is a catalyst for the reaction; the nanoparticulate component is heated by magnetic induction in order to reach a temperature within the range of temperatures T; and the reaction product(s) formed on the surface of the nanoparticulate component are recovered. A catalytic composition includes a ferromagnetic nanoparticulate component that can be heated by magnetic induction to the reaction temperature, whose surface thereof is at least partially formed by a catalyst compound for the reaction. The catalyst is heated by the effect of the magnetic field.

Abstract: A monoclonal chimeric immunoglobulin wherein the heavy chains and the light chains are human by nature in their constant parts, in particular, the heavy chain constant parts are chosen from the group formed of the heavy chain constant parts of an IgA, of an IgG or of an IgM and the light chain constant parts are chosen from the group formed of the kappa chains and the lambda chains, and the light chain and the heavy chain variable parts are chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens. A process for standardization of the screening and for quantification of anti-HLA antibodies in a liquid medium is also described.

Abstract: Polypeptides belonging to the family of late proteins of the cornified envelope (LCE), fragments of the polypeptide, isolated nucleotide sequences encoding the polypeptides, and cosmetic and/or pharmaceutical compositions containing such polypeptides are described. The polypeptides have cosmetic and/or therapeutic use to reinforce the barrier function of the epidermis, prevent and/or treat the signs of skin dryness and prevent and/or treat disorders of the barrier function or the weakening of the epidermis.